Ariana Pelosci on Muck Rack

Ariana Pelosci

Verified
New York
As seen in: Cancer Network, Odyssey, EIN News, NewsBreak, American Journal of Managed Care, ONCOLOGY journal, CURE Magazine, OncLive, Contemporary OB/GYN, Dermatology Times, Targeted Oncology and
Assistant Managing Editor @cancernetwrk | University of Delaware ‘21 | Author of Roxy and Velvet’s Big Adventure
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ariana

Contact Ariana, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Top GI Oncology Trials of the Year, Ranked by Dr. Nicholas Hornstein

|
By Brandon Mancini, Ron DiGiaimo, Ariana Pelosci Verified
| ONCOLOGY journal Verified
CancerNetwork® spoke with Nicholas Hornstein, MD, PhD, a gastrointestinal oncologist at Northwell Health and a 2024 American Society of Clinical Oncology (ASCO) Young Investigator Award winner, about the most impactful clinical trials in gastrointestinal (GI) oncology over the past year, the role of social media in building oncology community, and what it means to be an early-career leader in a rapidly evolving field.
Open in Who Shared Issue with article?

FDA Grants Breakthrough Device Designation to Merlin CP-GEP in Early-Stage Melanoma

|
By Joshua F. Zeidner, Jorge Cortés, Ariana Pelosci Verified
| ONCOLOGY journal Verified
The FDA has granted breakthrough device designation to Merlin CP-GEP, a clinicopathologic gene expression profile (CP-GEP) test intended to support risk assessment and clinical decision-making in patients with early-stage cutaneous melanoma.1 The designation is intended to expedite development and regulatory review of technologies that may improve diagnosis or management of life-threatening disease.
Open in Who Shared Issue with article?

ASCO Breakthrough 2026 Wrap-Up: Precision Oncology, AI, and Biomarkers Define the Future of Cancer Care

|
By Yan Leyfman, Tim Cortese, Ariana Pelosci Verified
| ONCOLOGY journal Verified
The 2026 ASCO Breakthrough Meeting concluded with a strong focus on precision oncology, biomarker-driven treatment, and the implementation of emerging technologies, reinforcing the meeting's overarching message: the future of cancer care will be increasingly personalized, data-driven, and globally collaborative.
Open in Who Shared Issue with article?
See all 1,399 licensed articles (1,944 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified